UK health committee to investigate pharma regulation after Brexit
27-09-2017
The House of Lords is hearing from companies and regulators today on issues including the government’s life sciences strategy and Brexit’s impact on the industry.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
House of Lords; life sciences; Brexit; life sciences strategy; life sciences investment; Professor Sir John Bell
